Outcome of COVID-19 in Patients With Mantle Cell Lymphoma-Report From the European MCL Registry.
Journal
HemaSphere
ISSN: 2572-9241
Titre abrégé: Hemasphere
Pays: United States
ID NLM: 101740619
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
21
01
2022
accepted:
14
03
2022
entrez:
15
4
2022
pubmed:
16
4
2022
medline:
16
4
2022
Statut:
epublish
Résumé
Data on outcome of patients with mantle cell lymphoma (MCL) and COVID-19 infection are limited. The European MCL (EMCL) registry is a centralized registry of the EMCL network, collecting real-world information about treatments and disease courses. During the COVID-19 pandemic, additional data on MCL patients with COVID-19 infection were collected, aiming to identify risk factors for mortality from COVID-19. In our retrospective, multicenter, international study, we collected data from 63 MCL patients with a median age of 64 years (range, 44-84) in 9 countries with evidence of a COVID-19 infection between February 2020 and October 2021. The overall mortality rate was high (44.4%), especially in hospitalized patients (61%) and in patients with need for intensive care unit care (94%). Patients receiving rituximab had significantly poorer survival than patients not receiving rituximab (
Identifiants
pubmed: 35425889
doi: 10.1097/HS9.0000000000000711
pmc: PMC9000040
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e0711Informations de copyright
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.
Références
J Clin Oncol. 2020 Dec 20;38(36):4302-4316
pubmed: 33074750
N Engl J Med. 2013 Aug 8;369(6):507-16
pubmed: 23782157
Nature. 2021 Feb;590(7844):140-145
pubmed: 33137809
Oncotarget. 2017 Nov 03;8(68):112516-112529
pubmed: 29348844
Am J Hematol. 2022 Apr;97(4):E132-E135
pubmed: 35007350
Leukemia. 2021 Dec;35(12):3444-3454
pubmed: 34725454
Blood. 2019 Jun 13;133(24):2570-2574
pubmed: 30967367
Acta Oncol. 2021 Jan;60(1):13-19
pubmed: 33131376
Leukemia. 2019 Apr;33(4):844-862
pubmed: 30700842
Am J Hematol. 2021 Aug 1;96(8):934-944
pubmed: 33909916
Br J Cancer. 2011 Nov 22;105(11):1684-92
pubmed: 22045184
N Engl J Med. 2020 Apr 2;382(14):1331-1342
pubmed: 32242358
Haematologica. 2019 Feb;104(2):e68-e71
pubmed: 30190341
Hemasphere. 2021 Feb 10;5(3):e538
pubmed: 33604516
Blood Adv. 2022 Jan 11;6(1):327-338
pubmed: 34644385
World J Virol. 2021 Nov 25;10(6):312-325
pubmed: 34909405
N Engl J Med. 2012 Aug 9;367(6):520-31
pubmed: 22873532
JCO Glob Oncol. 2020 Jun;6:799-808
pubmed: 32511066
J Clin Oncol. 2021 Jul 10;39(20):2232-2246
pubmed: 34085538
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Eur J Cancer. 2020 Nov;139:43-50
pubmed: 32971510
Blood. 2020 Sep 3;136(10):1134-1143
pubmed: 32688395
Front Oncol. 2021 Nov 04;11:759108
pubmed: 34804957
Ann Oncol. 2021 Jun;32(6):787-800
pubmed: 33746047
PLoS Med. 2021 Sep 28;18(9):e1003773
pubmed: 34582441
Blood Adv. 2021 Jun 22;5(12):2577-2585
pubmed: 34152395
Blood. 2010 Nov 11;116(19):3724-34
pubmed: 20664057
J Med Virol. 2021 Feb;93(2):1099-1104
pubmed: 32776581
Lancet. 2016 Aug 6;388(10044):565-75
pubmed: 27313086
EClinicalMedicine. 2020 Oct;27:100549
pubmed: 33073216
Blood Cells Mol Dis. 2021 Mar;87:102525
pubmed: 33338697
Ann Oncol. 2017 Jul 1;28(suppl_4):iv62-iv71
pubmed: 28881919